The time course of drug effects

This review aims to introduce the concepts and principles underpinning the time course of drug effects. Models describing the time course of drug concentrations (pharmacokinetic models) and the ensuing concentration-effect (pharmacodynamics models) as well as the linked time-effect (pharmacokinetic-pharmacodynamic models) are introduced. Different types of drug time-effects models are discussed with examples which aim to explain the time course of onset, duration, and maximal effect that occurs from any given dosing schedule. These drug effects are also described in relation to disease progression models.

[1]  Ene I. Ette,et al.  Pharmacometrics : the science of quantitative pharmacology , 2007 .

[2]  William J Jusko,et al.  Diversity of mechanism-based pharmacodynamic models. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[3]  N H Holford,et al.  Drug treatment effects on disease progression. , 2001, Annual review of pharmacology and toxicology.

[4]  N. Holford.  Modelling Disease Progression , 2007 .

[5]  Davide Verotta,et al.  Pharmacokinetic–Pharmacodynamic Modelling: History and Perspectives , 2006, Journal of Pharmacokinetics and Pharmacodynamics.

[6]  L B Sheiner,et al.  Relationship between the pharmacokinetics and pharmacodynamics of procainamide , 1976, Clinical pharmacology and therapeutics.

[7]  M. Hammarlund-Udenaes,et al.  Prolactin release after remoxipride by an integrated pharmacokinetic-pharmacodynamic model with intra- and interindividual aspects. , 1995, The Journal of pharmacology and experimental therapeutics.

[8]  L. Sheiner,et al.  Understanding the Dose-Effect Relationship , 1981, Clinical pharmacokinetics.

[9]  D. Mould.  Developing Models of Disease Progression , 2006 .

[10]  Varun Garg,et al.  Comparison of four basic models of indirect pharmacodynamic responses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.

[11]  Adriaan Cleton,et al.  Application of a Combined “Effect Compartment/Indirect Response Model” to the Central Nervous System Effects of Tiagabine in the Rat , 1999, Journal of Pharmacokinetics and Biopharmaceutics.

[12]  K. Okumura,et al.  Effect of altered plasma protein binding on pharmacokinetics and pharmacodynamics of propranolol in rats after surgery: role of alpha-1-acid glycoprotein. , 1985, The Journal of pharmacology and experimental therapeutics.

[13]  Meindert Danhof,et al.  Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. , 2007, Annual review of pharmacology and toxicology.

[14]  Giles R. Scuderi,et al.  The Basic Principles , 2006 .

[15]  W J Jusko,et al.  Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. , 1998, British journal of clinical pharmacology.

[16]  S. Belknap,et al.  Effect kinetics of N‐acetylprocainamide‐induced QT interval prolongation , 1987, Clinical pharmacology and therapeutics.

[17]  R. Schoenwald,et al.  Pharmacokinetics in Drug Discovery and Development , 2002 .

[18]  W Ewy,et al.  Model‐based Drug Development , 2007, Clinical pharmacology and therapeutics.

[19]  W J Jusko,et al.  Physiologic indirect response models characterize diverse types of pharmacodynamic effects , 1994, Clinical pharmacology and therapeutics.

[20]  L B Sheiner,et al.  Kinetics of pharmacologic response. , 1982, Pharmacology & therapeutics.

[21]  Wojciech Krzyzanski,et al.  Mathematical Formalism and Characteristics of Four Basic Models of Indirect Pharmacodynamic Responses for Drug Infusions , 2004, Journal of Pharmacokinetics and Biopharmaceutics.

[22]  Hui C. Kimko,et al.  Simulation for Designing Clinical Trials : A Pharmacokinetic-Pharmacodynamic Modeling Perspective , 2002 .

[23]  D. Mould,et al.  Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa‐2a and a polyethylene glycol‐modified derivative in healthy subjects , 1996, Clinical pharmacology and therapeutics.

[24]  J. Wagner.  Pharmacokinetics for the Pharmaceutical Scientist , 1993 .

[25]  C. Shanks,et al.  Pharmacokinetic and pharmacodynamic modelling with pancuronium , 2004, European Journal of Clinical Pharmacology.

[26]  W. Jusko,et al.  Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics , 1996, Clinical pharmacology and therapeutics.

[27]  L B Sheiner,et al.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. , 1980, Clinical pharmacology and therapeutics.

[28]  G Levy,et al.  Kinetics of pharmacologic effects , 1966, Clinical pharmacology and therapeutics.